Radiopharm Theranostics Files 6-K Report

TL;DR

Radiopharm Theranostics filed a standard 6-K, confirming its foreign private issuer status and Australian base.

AI Summary

Radiopharm Theranostics Limited, a pharmaceutical preparations company, filed a Form 6-K on October 23, 2025. The filing is a report of a foreign private issuer for the month of October 2025, indicating it files annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.

Why It Matters

This filing provides routine disclosure for foreign private issuers, informing investors about the company's reporting status and basic corporate information.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new financial or operational information that would typically impact risk.

Key Numbers

• 001-41621 — Commission File Number (Identifies the company's SEC filing history)

Key Players & Entities

• Radiopharm Theranostics Limited (company) — Registrant
• 20251023 (date) — Filing Date
• October 2025 (date) — Reporting Period
• Carlton South, Victoria, Australia (location) — Principal Executive Office

FAQ

Filing Documents

• ea0262086-6k_radio.htm (6-K) — 12KB
• ea026208601ex99-1_radio.htm (EX-99.1) — 536KB
• ex99-1_001.jpg (GRAPHIC) — 2094KB
• ex99-1_002.jpg (GRAPHIC) — 1810KB
• 0001213900-25-101373.txt ( ) — 5925KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on October 22, 2025 titled: “Notice of Annual General Meeting/Proxy Form” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Notice of Annual General Meeting/Proxy Form 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: October 22, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR